Who Paid My Doc
Roland El Ghazal
Critical Care Medicine New Haven, CT Medical Doctor
NPI 1649465469 CMS profile 695314
20 York Street, Cb-2041, New Haven, CT 06510
General payments
$19,069
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$114,716
Through program year 2025, Roland El Ghazal of New Haven, CT is reported in the CMS Open Payments database as having received $19,069 across 37 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $114,716 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 94th percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $4,841 | 9 | |
| 2024 | General | $6,057 | 12 | |
| 2023 | General | $6,338 | 12 | |
| 2022 | General | $112 | 1 | |
| 2021 | General | $15 | 1 | |
| 2019 | General | $1,706 | 2 |
Beside peers
- Roland El Ghazal
- Critical Care Medicine median
- Middle half of Critical Care Medicine
- National median
In program year 2025, general payments to Roland El Ghazal were reported at $4,841. Among 2,664 Critical Care Medicine profiles paid that year, the median was $189 and the middle half received between $59 and $844.
Show as a table
| Year | Roland El Ghazal | Critical Care Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,706 | $149 | $51–$535 | $163 |
| 2020 | $0 | $110 | $30–$325 | $114 |
| 2021 | $15 | $125 | $34–$403 | $132 |
| 2022 | $112 | $157 | $49–$582 | $149 |
| 2023 | $6,338 | $162 | $56–$621 | $160 |
| 2024 | $6,057 | $168 | $53–$634 | $164 |
| 2025 | $4,841 | $189 | $59–$844 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 16 drugsPart D claims
504
Drug cost
$105,823
Branded share of claims
54%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 63 | $56,945 | |
| Breo Ellipta Fluticasone/Vilanterol | Brand | 19 | $12,361 | |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | Brand | 11 | $7,880 | |
| Spiriva Handihaler Tiotropium Bromide | Brand | 11 | $5,534 | |
| Wixela Inhub Fluticasone Propion/Salmeterol | Brand | 50 | $5,302 | |
| Symbicort Budesonide/Formoterol Fumarate | Brand | 12 | $4,668 | |
| Abrysvo Rsv Vacc, Pref A And Pref B/Pf | Brand | 13 | $4,076 | |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | Brand | 23 | $3,312 | |
| Albuterol Sulfate Hfa Albuterol Sulfate | Brand | 42 | $1,061 | |
| Ethambutol Hcl | Generic | 14 | $996 |
The 10 drugs with the highest cost, of 16 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,531 Part D prescribers listed as Critical Care (Intensivists); they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 54 billing codesPaid by Medicare
$70,706
Medicare patients
262
Services billed
727
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 46% | |
| COPD | 44% | |
| Ischemic heart disease | 40% | |
| Diabetes | 37% | |
| Heart failure | 37% | |
| Atrial fibrillation | 33% | |
| Chronic kidney disease | 31% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Pcv20 vaccine im 90677 | Office | 26 | 26 | $7,265 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
37 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Critical Care Medicine in Connecticut
Richard Silverman
Critical Care Medicine · Waterbury, CT
David Hill
Critical Care Medicine · Waterbury, CT
Philip Simkovitz
Critical Care Medicine · Trumbull, CT
David Kaufman
Critical Care Medicine · Bridgeport, CT
Robert McDonald
Critical Care Medicine · Waterbury, CT
Akhil Khosla
Critical Care Medicine · New Haven, CT
Related records
Critical Care Medicine in Connecticut
Practitioners in the same specialty and state, ranked by reported value.
All Critical Care Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Connecticut
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.